GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 447,259 Shares

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68. Following the completion of the transaction, the insider owned 913,592 shares in the company, valued at $3,215,843.84. This trade represents a 32.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $3.45 on Friday. The stock has a fifty day moving average price of $3.13 and a 200 day moving average price of $2.63. GoodRx Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $5.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market cap of $1.18 billion, a PE ratio of 86.27, a P/E/G ratio of 1.77 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. GoodRx’s revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.09 EPS. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Hedge Funds Weigh In On GoodRx

A number of institutional investors have recently added to or reduced their stakes in the company. Essential Partners LLC boosted its position in GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after buying an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC purchased a new stake in shares of GoodRx during the fourth quarter worth about $29,000. SG Americas Securities LLC acquired a new position in shares of GoodRx in the first quarter worth about $29,000. Headlands Technologies LLC purchased a new position in GoodRx in the second quarter valued at about $30,000. Finally, Krilogy Financial LLC purchased a new position in GoodRx in the first quarter valued at about $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GDRX. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $4.00 price target on shares of GoodRx in a report on Friday, August 7th. Wells Fargo & Company raised their price target on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. TD Cowen lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Citigroup increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.23.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.